1. previous hypersensitivity or allergic reactions to clazakizumab 2. lactating or pregnant females 3. patients with latent tuberculosis (tb) and who are not receiving treatment 4. patients with active tb 5. patients with known active inflammatory bowel disease, untreated diverticulitis, or gastrointestinal perforation 6. requiring mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 7. a significantly abnormal general serum screening lab result defined as a white blood cell (wbc) count \< 3.0 x 10\^3/ml, a hemoglobin (hgb) \< 8.0 g/dl, a platelet count \< 50 x 10\^3/ml, an aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 5 times upper limit normal 8. participation in another clinical trial investigating covid-19-aimed agents 9. presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.

1. previous hypersensitivity or allergic reactions to clazakizumab 2. lactating or pregnant females 3. patients with latent tuberculosis (tb) and who are not receiving treatment 4. patients with active tb 5. patients with known active inflammatory bowel disease, untreated diverticulitis, or gastrointestinal perforation 6. requiring mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 7. a significantly abnormal general serum screening lab result defined as a white blood cell (wbc) count \< 3.0 x 10\^3/ml, a hemoglobin (hgb) \< 8.0 g/dl, a platelet count \< 50 x 10\^3/ml, an aspartate aminotransferase (ast) or alanine aminotransferase (alt) \> 5 times upper limit normal 8. participation in another clinical trial investigating covid-19-aimed agents 9. presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.

previous hypersensitivity or allergic reactions to clazakizumab lactating or pregnant females patients with latent tuberculosis (tb) and who are not receiving treatment patients with active tb patients with known active inflammatory bowel disease, untreated diverticulitis, or gastrointestinal perforation requiring mechanical ventilation or extracorporeal membrane oxygenation (ecmo) a significantly abnormal general serum screening lab result defined as a white blood cell (wbc) count < 3.0 x 10^3/ml, a hemoglobin (hgb) < 8.0 g/dl, a platelet count < 50 x 10^3/ml, an aspartate aminotransferase (ast) or alanine aminotransferase (alt) > 5 times upper limit normal participation in another clinical trial investigating covid-19-aimed agents presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.

previous hypersensitivity or allergic reactions to clazakizumab lactating or pregnant females patients with latent tuberculosis (tb) and who are not receiving treatment patients with active tb patients with known active inflammatory bowel disease, untreated diverticulitis, or gastrointestinal perforation requiring mechanical ventilation or extracorporeal membrane oxygenation (ecmo) a significantly abnormal general serum screening lab result defined as a white blood cell (wbc) count < 3.0 x 10^3/ml, a hemoglobin (hgb) < 8.0 g/dl, a platelet count < 50 x 10^3/ml, an aspartate aminotransferase (ast) or alanine aminotransferase (alt) > 5 times upper limit normal participation in another clinical trial investigating covid-19-aimed agents presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.

1. previous hypersensitivity or allergic reactions to clazakizumab 2. lactating or pregnant females 3. patients with latent tuberculosis (tb) and who are not receiving treatment 4. patients with active tb 5. patients with known active inflammatory bowel disease, untreated diverticulitis, or gastrointestinal perforation 6. requiring mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 7. a significantly abnormal general serum screening lab result defined as a white blood cell (wbc) count < 3.0 x 10^3/ml, a hemoglobin (hgb) < 8.0 g/dl, a platelet count < 50 x 10^3/ml, an aspartate aminotransferase (ast) or alanine aminotransferase (alt) > 5 times upper limit normal 8. participation in another clinical trial investigating covid-19-aimed agents 9. presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.

1. previous hypersensitivity or allergic reactions to clazakizumab 2. lactating or pregnant females 3. patients with latent tuberculosis (tb) and who are not receiving treatment 4. patients with active tb 5. patients with known active inflammatory bowel disease, untreated diverticulitis, or gastrointestinal perforation 6. requiring mechanical ventilation or extracorporeal membrane oxygenation (ecmo) 7. a significantly abnormal general serum screening lab result defined as a white blood cell (wbc) count < 3.0 x 10^3/ml, a hemoglobin (hgb) < 8.0 g/dl, a platelet count < 50 x 10^3/ml, an aspartate aminotransferase (ast) or alanine aminotransferase (alt) > 5 times upper limit normal 8. participation in another clinical trial investigating covid-19-aimed agents 9. presence of any medical or psychosocial condition, which the investigator believes, would hinder adherence to the study requirements.